Stacy Loeb

List of Publications by Year in Descending Order

201 papers	6,269 citations	39 h-index	75 g-index
248 ext. papers	7,989 ext. citations	4.8 avg, IF	6.12 L-index

#	Paper	IF	Citations
201	EDITORIAL COMMENT.. *Urology*, **2022**, 159, 27	1.6	
200	Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.. *Journal of Urology*, **2022**, 101097JU0000000000002257	2.5	2
199	Social Media and Professional Development for Oncology Professionals.. *JCO Oncology Practice*, **2022**, OP2100761	2.3	0
198	Online Medical Misinformation in Cancer: Distinguishing Fact From Fiction.. *JCO Oncology Practice*, **2022**, OP2100764	2.3	1
197	Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care.. *Sleep Medicine*, **2022**, 94, 38-53	4.6	0
196	0225 An assessment of the information quality, understandability, and actionability of popular YouTube videos on sleep and sleep disorders. *Sleep*, **2022**, 45, A102-A102	1.1	
195	Factors that influence cliniciansÕ decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study. *BMJ Open*, **2021**, 11, e048347	2	
194	Association of Plant-Based Diet Index with Prostate Cancer Risk. *American Journal of Clinical Nutrition*, **2021**,	7	4
193	Perspectives of Residency Applicants and Program Directors on the Role of Social Media in the 2021 Urology Residency Match. *Urology*, **2021**,	1.6	2
192	A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines. *European Urology Focus*, **2021**, 7, 1195-1204	5.1	5
191	#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology. *European Urology Focus*, **2021**, 7, 890-893	5.1	3
190	Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer. *European Urology Open Science*, **2021**, 25, 1-4	0.9	1
189	Barriers and facilitators of germline genetic evaluation for prostate cancer. *Prostate*, **2021**, 81, 754-764	4.2	2
188	TikTok and prostate cancer: misinformation and quality of information using validated questionnaires. *BJU International*, **2021**, 128, 435-437	5.6	8
187	Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. *Cancer*, **2021**, 127, 3985-3990	6.4	1
186	Climate Change Impact of Virtual Urology Meetings. *European Urology*, **2021**, 80, 121-122	10.2	
185	Quality of Bladder Cancer Information on YouTube. *European Urology*, **2021**, 79, 56-59	10.2	10

184	Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees. *Urology*, **2021**, 147, 64-67	1.6	8
183	Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club. *European Urology Focus*, **2021**, 7, 482-488	5.1	12
182	Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. *European Urology Oncology*, **2021**, 4, 1-9	6.7	11
181	Prostate cancer. *Nature Reviews Disease Primers*, **2021**, 7, 9	51.1	72
180	B2B: Prostate Cancer. *Soci Internationale D urologie Journal*, **2021**, 2, S30-S50	0.1	
179	Growth of the Twitter Presence of Academic Urology Training Programs and Its Catalysis by the COVID-19 Pandemic. *European Urology*, **2021**, 80, 261-263	10.2	4
178	An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts. *Urology*, **2021**, 154, 120-126	1.6	0
177	Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis. *Prostate Cancer and Prostatic Diseases*, **2021**,	6.2	4
176	Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. *JMIR Cancer*, **2021**, 7, e27063	3.2	1
175	Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness. *Radiology*, **2021**, 300, 594-604	20.5	1
174	A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. *European Urology*, **2021**, 80, 442-449	10.2	10
173	Reply to Laurence Klotz Letter to the Editor re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. *European Urology*, **2021**, 80, e101	10.2	3
172	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *Journal of Clinical Oncology*, **2020**, 38, 2798-2811	2.2	80
171	Global survey evaluating drawbacks of social media usage for practising urologists. *BJU International*, **2020**, 126, 7-8	5.6	3
170	Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System. *European Urology*, **2020**, 77, 683-686	10.2	7
169	Pelvic organ prolapse on YouTube: evaluation of consumer information. *BJU International*, **2020**, 125, 759-760	5.6	7
168	Racial disparities and online health information: YouTube and prostate cancer clinical trials. *BJU International*, **2020**, 126, 11-13	5.6	6
167	Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. *Urology*, **2020**, 141, 119-124	1.6	9

166	Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations - #SoME_Impact Score: Observational Analysis. *Journal of Medical Internet Research*, **2020**, 22, e12288	7.6	10
165	Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study. *Journal of Medical Internet Research*, **2020**, 22, e21875	7.6	19
164	A Global Survey on the Impact of COVID-19 on Urological Services. *European Urology*, **2020**, 78, 265-275	10.2	81
163	Impact of the Internet on Patient-Physician Communication. *European Urology Focus*, **2020**, 6, 440-444	5.1	8
162	Understanding the Composition of a Successful Tweet in Urology. *European Urology Focus*, **2020**, 6, 450-457	5.1	3
161	Guideline of guidelines: social media in urology. *BJU International*, **2020**, 125, 379-382	5.6	12
160	Fake News: Spread of Misinformation about Urological Conditions on Social Media. *European Urology Focus*, **2020**, 6, 437-439	5.1	15
159	A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners. *Journal of Sexual Medicine*, **2020**, 17, 361-363	1.1	1
158	Using data from an online health community to examine the impact of prostate cancer on sleep. *BJU International*, **2020**, 125, 634-635	5.6	2
157	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. *European Urology*, **2020**, 78, 731-742	10.2	23
156	Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19. *Urology*, **2020**, 144, 269-270	1.6	3
155	Telemedicine and smart working: Spanish adaptation of the European Association of Urology recommendations. *Actas Urológicas Españolas*, **2020**, 44, 644-652	0.7	2
154	Telemedicine and Smart Working: Recommendations of the European Association of Urology. *European Urology*, **2020**, 78, 812-819	10.2	24
153	Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation. *Cancer Treatment and Research Communications*, **2020**, 25, 100212	2	7
152	A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study. *Urology*, **2020**, 145, 113-119	1.6	1
151	Increasing Social Media Use in Urology: 2017 American Urological Association Survey. *European Urology Focus*, **2020**, 6, 605-608	5.1	21
150	Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019. *BJU International*, **2020**, 125, 173-181	5.6	21
149	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 179-183	6.2	4

148	Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination. *European Urology*, **2019**, 75, 881-882	10.2	10
147	Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 145-149	2.8	3
146	Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology. *European Urology*, **2019**, 76, 261-264	10.2	4
145	Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. *Anticancer Research*, **2019**, 39, 2467-2473	2.3	6
144	Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer. *BJU International* , **2019**, 124, 578	5.6	9
143	Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening. *BJU International*, **2019**, 124, 363-364	5.6	0
142	The Urology Care Foundation - trusted online resources in an era of misinformation. *Nature Reviews Urology*, **2019**, 16, 637-638	5.5	2
141	Does Dr Google give good advice about prostate cancer?. *BJU International*, **2019**, 124, 548-549	5.6	
140	Perceived Patient-Provider Communication Quality and Sociodemographic Factors Associated With Watching Health-Related Videos on YouTube: A Cross-Sectional Analysis. *Journal of Medical Internet Research*, **2019**, 21, e13512	7.6	34
139	Media and Social Media **2019**, 115-122		
138	Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube. *European Urology*, **2019**, 75, 564-567	10.2	108
137	Prostate cancer and social media. *Nature Reviews Urology*, **2018**, 15, 422-429	5.5	13
136	Public online reporting from a nationwide population-based clinical prostate cancer register. *BJU International*, **2018**, 122, 8-10	5.6	7
135	Informational needs during active surveillance for prostate cancer: A qualitative study. *Patient Education and Counseling*, **2018**, 101, 241-247	3.1	9
134	Crowdfunding for prostate cancer and breast cancer. *BJU International*, **2018**, 122, 723-725	5.6	8
133	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. *Journal of Clinical Oncology*, **2018**, 36, 581-590	2.2	107
132	Biomarkers in active surveillance. *Translational Andrology and Urology*, **2018**, 7, 155-159	2.3	9
131	Health state utilities among contemporary prostate cancer patients on active surveillance. *Translational Andrology and Urology*, **2018**, 7, 197-202	2.3	3

130	Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. *European Urology*, **2018**, 74, 644-650	10.2	38
129	Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients. *Urology Practice*, **2017**, 4, 315-321	0.8	3
128	Editorial Comment. *Journal of Urology*, **2017**, 197, 626	2.5	
127	Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology. *BJU International*, **2017**, 119, 820-822	5.6	21
126	Tweet this: how advocacy for breast and prostate cancers stacks up on social media. *BJU International*, **2017**, 120, 461-463	5.6	10
125	Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?. *BJU International*, **2017**, 120, 441-454	5.6	34
124	Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators. *Urologic Clinics of North America*, **2017**, 44, 517-524	2.9	13
123	Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. *Journal of Clinical Oncology*, **2017**, 35, 1430-1436	2.2	44
122	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. *European Urology*, **2017**, 72, 899-907	10.2	15
121	Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	16
120	Re: The Prostate Health Index Adds Predictive Value to Multi-parametric MRI in Detecting Significant Prostate Cancers in a Repeat Biopsy Population. *European Urology*, **2017**, 72, 654-655	10.2	1
119	Twitter Activity Associated With U.S. News and World Report Reputation Scores for Urology Departments. *Urology*, **2017**, 108, 11-16	1.6	25
118	Genomic testing for localized prostate cancer: where do we go from here?. *Current Opinion in Urology*, **2017**, 27, 495-499	2.8	25
117	Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. *BJU International*, **2017**, 120, 61-68	5.6	54
116	Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. *JAMA Oncology*, **2017**, 3, 1393-1398	13.4	84
115	Complications After Systematic, Random, and Image-guided Prostate Biopsy. *European Urology*, **2017**, 71, 353-365	10.2	225
114	Qualitative study on decision-making by prostate cancer physicians during active surveillance. *BJU International*, **2017**, 120, 32-39	5.6	23
113	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. *European Urology*, **2017**, 71, 330-336	10.2	42

112	Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. *Journal of Endourology*, **2016**, 30, 1291-1295	2.7	4
111	Curating a Digital Identity: What Urologists Need to Know About Social Media. *Urology*, **2016**, 97, 5-7	1.6	4
110	Screening for familial and hereditary prostate cancer. *International Journal of Cancer*, **2016**, 138, 2579-91	7.5	33
109	Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study. *European Urology*, **2016**, 70, 1083-1085	10.2	12
108	Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. *European Urology*, **2016**, 69, 1135-41	10.2	87
107	Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. *European Urology*, **2016**, 70, 824-828	10.2	14
106	How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. *Journal of Urology*, **2016**, 196, 721-6	2.5	53
105	Active surveillance for prostate cancer: current evidence and contemporary state of practice. *Nature Reviews Urology*, **2016**, 13, 205-15	5.5	143
104	The Prostate Health Index: Its Utility in Prostate Cancer Detection. *Urologic Clinics of North America*, **2016**, 43, 1-6	2.9	31
103	Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. *Canadian Urological Association Journal*, **2016**, 10, 39-44	1.2	37
102	Phosphodiesterase type 5 inhibitors (PDE5i) and prostate cancer recurrence.. *Journal of Clinical Oncology*, **2016**, 34, 55-55	2.2	
101	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e235-45	7.1	22
100	Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study. *BJU International*, **2016**, 118, 302-6	5.6	11
99	Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 377-83	2.8	35
98	Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711. *Journal of Urology*, **2016**, 195, 1172-3	2.5	
97	Immediate versus delayed prostatectomy: Nationwide population-based study (.). *Scandinavian Journal of Urology*, **2016**, 50, 246-54	1.6	18
96	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. *Urology*, **2016**, 96, 116-120	1.6	8
95	Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. *JAMA - Journal of the American Medical Association*, **2015**, 313, 2449-55	27.4	62

94	The prostate health index selectively identifies clinically significant prostate cancer. *Journal of Urology*, **2015**, 193, 1163-9	2.5	171
93	Do environmental factors modify the genetic risk of prostate cancer?. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 213-20	4	9
92	Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. *European Urology*, **2015**, 67, 619-26	10.2	102
91	Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. *European Urology Focus*, **2015**, 1, 137-146	5.1	13
90	Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer. *European Urology*, **2015**, 68, 907	10.2	1
89	Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigen. *BJU International*, **2015**, 116, 65-71	5.6	32
88	Updated Survey of Social Media Use by Members of the American Urological Association. *Urology Practice*, **2015**, 2, 138-143	0.8	12
87	Editorial Comment. *Urology*, **2015**, 86, 504-5	1.6	
86	Five-year nationwide follow-up study of active surveillance for prostate cancer. *European Urology*, **2015**, 67, 233-8	10.2	56
85	The Comparison of Magnetic Resonance Image-Guided Targeted Biopsy Versus Standard Template Saturation Biopsy in the Detection of Prostate Cancer. *Reviews in Urology*, **2015**, 17, 110-1	1	
84	Standard and Targeted Biopsy During Follow-up for Active Surveillance. *Reviews in Urology*, **2015**, 17, 112-3	1	1
83	MRI/Ultrasound Fusion Biopsy Versus Standard 12-Core Biopsy. *Reviews in Urology*, **2015**, 17, 113-5	1	4
82	Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals. *Canadian Urological Association Journal*, **2015**, 9, E713-7	1.2	48
81	Overdiagnosis and overtreatment of prostate cancer. *European Urology*, **2014**, 65, 1046-55	10.2	528
80	Editorial comment. *Urology*, **2014**, 84, 1014	1.6	
79	Editorial comment. *Urology*, **2014**, 84, 1006-7	1.6	
78	Editorial comment. *Urology*, **2014**, 84, 1167	1.6	
77	Guideline of guidelines: prostate cancer screening. *BJU International*, **2014**, 114, 323-5	5.6	37

76	Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. *Journal of Urology*, **2014**, 192, 1116-22	2.5	63
75	Engaging responsibly with social media: the BJUI guidelines. *BJU International*, **2014**, 114, 9-11	5.6	63
74	Use of social media in urology: data from the American Urological Association (AUA). *BJU International*, **2014**, 113, 993-8	5.6	114
73	Radical prostatectomy outcomes during prostate-specific antigen era in Ireland compared to a matched American population. *Journal of Clinical Urology*, **2014**, 7, 170-175	0.2	
72	Prostate cancer risk alleles are associated with prostate cancer volume and prostate size. *Journal of Urology*, **2014**, 191, 1733-6	2.5	8
71	Prostate cancer screening: highlights from the 29th European association of urology congress stockholm, sweden, april 11-15, 2014. *Reviews in Urology*, **2014**, 16, 90-1	1	4
70	Heterogeneity in active surveillance protocols worldwide. *Reviews in Urology*, **2014**, 16, 202-3	1	7
69	The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients. *Current Translational Geriatrics and Experimental Gerontology Reports*, **2013**, 2, 51-57		2
68	Systematic review of complications of prostate biopsy. *European Urology*, **2013**, 64, 876-92	10.2	564
67	Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. *Cancer Causes and Control*, **2013**, 24, 383-90	2.8	8
66	Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. *Journal of Urology*, **2013**, 189, 867-70	2.5	57
65	Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. *Journal of Urology*, **2013**, 189, 1702-6	2.5	41
64	Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. *Journal of Urology*, **2013**, 190, 1742-9	2.5	93
63	Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?. *Current Opinion in Urology*, **2013**, 23, 2-4	2.8	5
62	Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 281-5	7.3	3
61	Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. *Reviews in Urology*, **2013**, 15, 72-81	1	
60	Advances in localized prostate cancer: highlights from the 2012 friends of Israel urological symposium, july 3-5, 2012, tel aviv, Israel. *Reviews in Urology*, **2013**, 15, 82-3	1	
59	Updates in the care and management of prostate cancer: highlights from the 2013 prostate cancer world congress, august 6-10, 2013, melbourne, australia. *Reviews in Urology*, **2013**, 15, 185-7	1	

58	More aggressive prostate cancer in elderly men. *Reviews in Urology*, **2013**, 15, 202-4	1	6
57	PSA Velocity in Risk Stratification of Prostate Cancer. *Reviews in Urology*, **2013**, 15, 204-6	1	4
56	Patient Perceptions and Shared Decisions About PSA Screening. *Reviews in Urology*, **2013**, 15, 206-7	1	
55	Baseline prostate-specific antigen testing at a young age. *European Urology*, **2012**, 61, 1-7	10.2	66
54	Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. *European Urology*, **2012**, 61, 1110-4	10.2	215
53	Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. *BJU International*, **2012**, 109, 508-13; discussion 513-4	5.6	29
52	Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam. *BJU International*, **2012**, 110, 1678-83	5.6	11
51	External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 584-9	2.8	14
50	Editorial comment. *Urology*, **2012**, 79, 661	1.6	
49	Novel technique for fragment removal after percutaneous management of large-volume neobladder calculi. *Urology*, **2012**, 80, 474-6	1.6	4
48	Innovation in Endourology and Minimally Invasive Surgery: Highlights From the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan. *Reviews in Urology*, **2012**, 14, 28-30	1	
47	Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. *Urology*, **2011**, 77, 143-7	1.6	15
46	Can we stop prostate specific antigen testing 10 years after radical prostatectomy?. *Journal of Urology*, **2011**, 186, 500-5	2.5	40
45	Use of empiric antibiotics in the setting of an increased prostate specific antigen: pro. *Journal of Urology*, **2011**, 186, 17-9	2.5	1
44	Complications after prostate biopsy: data from SEER-Medicare. *Journal of Urology*, **2011**, 186, 1830-4	2.5	489
43	GENETIC BASIS FOR PROSTATE CANCER **2011**, 39-52		
42	Re: randomised prostate cancer screening trial: 20 year follow-up. *European Urology*, **2011**, 60, 1306-7	10.2	2
41	Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. *World Journal of Urology*, **2011**, 29, 11-4	4	4

40	Reply to P.F. Pinksy. *Journal of Clinical Oncology*, **2011**, 29, 3337-3337	2.2	2
39	Germline sequence variants and prostate-specific antigen interpretation. *Clinical Chemistry*, **2011**, 57, 662-3	5.5	3
38	What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?. *Journal of Clinical Oncology*, **2011**, 29, 464-7	2.2	73
37	Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. *Reviews in Urology*, **2011**, 13, e191-5	1	17
36	Should prostate-specific antigen velocity be abandoned?. *Asian Journal of Andrology*, **2011**, 13, 359-60	2.8	
35	Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes?. *BJU International*, **2010**, 105, 1510-3	5.6	47
34	Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging. *BJU International*, **2010**, 106, 28-31	5.6	
33	Benign prostate glands at the bladder neck margin in robotic vs open radical prostatectomy. *BJU International*, **2010**, 105, 1446-9	5.6	12
32	Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. *Journal of Clinical Oncology*, **2010**, 28, 2810-6	2.2	192
31	Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. *Journal of Urology*, **2010**, 184, 157-61	2.5	12
30	What are the outcomes of radical prostatectomy for high-risk prostate cancer?. *Urology*, **2010**, 76, 710-4	1.6	106
29	The vanishing prostate cancer phenomenon. *Urology*, **2010**, 76, 605-7	1.6	8
28	Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. *Journal of Urology*, **2010**, 183, 1816-21	2.5	8
27	Prostate-specific antigen screening: pro. *Current Opinion in Urology*, **2010**, 20, 185-8	2.8	15
26	Diabetes mellitus and prostate cancer risk. *Expert Review of Endocrinology and Metabolism*, **2010**, 5, 787-789	4.8	
25	Open versus minimally invasive radical prostatectomy. *Reviews in Urology*, **2010**, 12, 64-5	1	
24	What is the true mortality benefit of prostate-specific antigen screening?. *Reviews in Urology*, **2010**, 12, 66-7	1	
23	A case of gastrointestinal stromal tumor diagnosed on prostate biopsy. *Nature Reviews Urology*, **2009**, 6, 54-7		2

22	Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. *European Urology*, **2009**, 55, 523-4	10.2	
21	Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?. *BJU International*, **2009**, 104, 1200-3	5.6	5
20	Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. *Urology*, **2009**, 73, 947-9	1.6	3
19	Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). *Urologic Oncology: Seminars and Original Investigations*, **2009**, 27, 64-6	2.8	30
18	Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. *Journal of Urology*, **2009**, 182, 2646-51	2.5	18
17	What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?. *Nature Reviews Urology*, **2009**, 6, 68-9		14
16	Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. *Journal of Urology*, **2009**, 182, 101-4; discussion 105	2.5	24
15	Editorial comment. *Journal of Urology*, **2009**, 182, 2701	2.5	
14	Risk factors, prevention and early detection of prostate cancer. *Primary Care - Clinics in Office Practice*, **2009**, 36, 603-21	2.2	5
13	Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. *Journal of Urology*, **2009**, 182, 1458-62	2.5	76
12	Progression after radical prostatectomy for men in their thirties compared to older men. *BJU International*, **2008**, 101, 1503-6	5.6	33
11	Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. *European Urology*, **2008**, 54, 88-94	10.2	19
10	PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. *European Urology*, **2008**, 54, 1073-80	10.2	39
9	The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. *European Urology*, **2008**, 54, 978-979	10.2	7
8	Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer. *Urology*, **2008**, 72, 143-7	1.6	12
7	Prostate specific antigen assay standardization bias could affect clinical decision making. *Journal of Urology*, **2008**, 180, 1959-62; discussion 1962-3	2.5	21
6	Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. *Journal of Urology*, **2007**, 178, 2348-52; discussion 2352-3	2.5	21
5	Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. *Journal of Urology*, **2006**, 175, 902-6	2.5	62

4	Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. *Urology*, **2006**, 67, 316-20	1.6	137
3	Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. *Journal of Urology*, **2005**, 173, 63-5	2.5	53
2	Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study (Preprint)		1
1	Research communication: Poor sleep health and quality of life among caregivers of patients with prostate cancer. *BJUI Compass*,	0.9	0